NSD3 and nut midline carcinoma: Notably, patients with NUT carcinoma in the head and neck region and who exhibit the NSD3::NUTM1 fusion tend to have a notably improved prognosis compared to the typical NUT carcinoma median survival of 6.5 months, with a median overall survival of 36.5 months [13].